Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic
  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Cases of COVID variant BA.2.86 have tripled in 2 weeks, says CDC report

Cases of the COVID-19 variant Omicron BA.2.86 have tripled in two weeks, comprising between 5% and 15% of all infections, according to the CDC. A doctor weighs in on the risk.

Cases of the COVID-19 variant Omicron BA.2.86, also known as Pirola, have tripled in two weeks, comprising between 5% and 15% of all infections, according to the Centers for Disease Control and Prevention (CDC).

The COVID-19 variant Omicron BA.2.86 — as well as its offshoots, including JN.1 — has been reclassified as a "variant of interest" by the World Health Organization (WHO).

Despite its prevalence, BA.2.86 "does not appear to be driving increases in infections or hospitalizations in the United States," the CDC stated in its report.

OVER HALF THE PEOPLE WHO GET COVID HAVE LINGERING SYMPTOMS AFTER 3 YEARS, NEW STUDY FINDS

Both the CDC and WHO agree that "the public health risk posed by this variant is low compared with other circulating variants."

The updated COVID-19 vaccines that were approved by the FDA in September are believed to "increase protection against BA.2.86, as they do for other variants," the CDC noted.

"To date, existing vaccines have been very effective in protecting people, particularly those who have been boosted multiple times through a vaccine or natural infection, not only from symptomatic infection, but importantly from severe disease, hospitalization and death," said Richard Reithinger, PhD, a distinguished research fellow in the Global Health Division at International Development Group in Washington, D.C., in a statement to Fox News Digital.

COVID IS NOT A CONCERN FOR AMERICANS HEADING INTO CHRISTMAS, OTHER HOLIDAYS, SAYS SURVEY: 'JUST ANOTHER VIRUS'

The CDC said it is not clear whether BA.2.86 causes different symptoms — but noted that most variants produce similar effects.

"The types of symptoms and how severe they are usually depend more on a person’s immunity than which variant causes the infection," the statement said.

The variant is also expected to respond to the current tests and treatments.

Reithinger noted that while the pandemic is officially over, COVID-19 is not a thing of the past. 

"A concern of the new BA.2.86 variant was that because it has 35 mutations in the spike protein, it would be able to evade the immune response more readily than other variants that emerged in the last couple of months," he told Fox News Digital. 

"Early clinical data does not seem to indicate this being the case."

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

The increase in BA.2.86 cases is due to the U.S. entering the "COVID-19 season" and also a sufficient number of people having developed non-BA.2.86 immunity, according to the doctor.

Outside of vaccines, Reithinger recommends that high-risk groups adopt risk-mitigating behaviors, including wearing masks, frequently washing hands and avoiding crowded environments.

"People — particularly those with greater risk of infection and severe disease — should continue to be sensitized and vigilant about COVID-19 and the disease it may cause," he told Fox News Digital.

"People who are at greater risk of infection and severe disease should consult with their physicians about whether they should be administered one of the currently available boosters," he added.

Those at highest risk include people older than 60 years, the immunocompromised, those with comorbidities such as asthma and diabetes, and people working in high-risk-of-exposure employment, such as the service industry, Reithinger noted.

For more Health articles, visit www.foxnews/health.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.